Zymeworks to Present at J.P. Morgan Healthcare Conference and Host Two Webcasts in January to Provide Updates on its Lead Clinical Programs Zanidatamab and ZW49

On January 7, 2021 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported that management will present at the upcoming 39th Annual J.P. Morgan Healthcare Conference (Press release, Zymeworks, JAN 7, 2021, View Source [SID1234573628]). In addition, Zymeworks will host two webcasts in January to discuss the zanidatamab clinical data presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium (ASCO GI) and provide an update on ZW49’s clinical progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan Healthcare Conference Presentation

The J.P. Morgan presentation will take place on Monday, January 11, 2021 at 3:40 p.m. ET.

Zanidatamab ASCO (Free ASCO Whitepaper) GI Webcast

Zymeworks will host a webcast on Friday, January 15, 2021 at 5:00 pm ET to discuss the clinical results for the Company’s HER2 bispecific, zanidatamab, in biliary tract cancer and gastroesophageal cancer presented at ASCO (Free ASCO Whitepaper) GI earlier that day. The data will be discussed by lead investigator, Dr. Funda Meric-Bernstam, M.D., Clinical Investigator and Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

ZW49 Clinical Update Webcast

Zymeworks will host a webcast on Wednesday, January 27, 2021 at 4:30 pm ET to provide an update on clinical progress from the Phase 1 dose-escalation study for the Company’s HER2 bispecific antibody-drug conjugate, ZW49.

Interested parties can access these live webcasts via a link from Zymeworks’ website at View Source Participants are encouraged to connect five to ten minutes prior to the scheduled start time. A recorded replay will also be available on the website shortly after the webcast concludes.